Pre-made Tavolimab benchmark antibody ( Whole mAb, anti-TNFSF4/OX40 therapeutic antibody, Anti-CD134L/CD252/GP34/OX-40L/OX4OL/TNLG2B/TXGP1 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-553
Pre-Made Tavolimab biosimilar, Whole mAb, Anti-TNFSF4/OX40 Antibody: Anti-CD134L/CD252/GP34/OX-40L/OX4OL/TNLG2B/TXGP1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Tavolimab (MEDI 0562), a humanised IgG1κ monoclonal antibody agonist of OX40, was being developed by MedImmune for the treatment of solid tumours, including ovarian cancer.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Tavolimab biosimilar, Whole mAb, Anti-TNFSF4/OX40 Antibody: Anti-CD134L/CD252/GP34/OX-40L/OX4OL/TNLG2B/TXGP1 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||European Network of Gynaecological Oncological Trial Groups;MedImmune|
|Conditions Discontinued||Ovarian cancer;Solid tumours|